The content on this site is intended for healthcare professionals only
Dr Gil Morgan from OncoAlert gives his oncology highlights from social media for the week of September 1-7, 2023.
He begins by highlighting the announcement of two additional FDA breakthrough therapy designations for trastuzumab deruxtecan based in promising results across multiple Her2 expressing advanced solid tumours.
Dr Morgan also discusses the coopERA phase 2 trial which examined giredestrant as a potential alternative to current endocrine therapies for untreated early breast cancer.
He also mentions a study which investigates the impact of exercise and nutrition intervention on chemotherapy completion and pathologic complete response in breast cancer patients. Then he highlights an article which reviews the current state of palliative cancer care.
Dr Morgan concludes by outlining a study comparing bladder sparing trimodal therapy and radical cystectomy that showed equivalent survival outcomes for non-metastatic clinically node positive bladder cancer patients.
Follow Dr Morgan on twitter: @OncoAlert
Follow ecancer on twitter: @ecancer
Best practice in precision medicine for prostate cancer
Burden and trends of breast cancer worldwide: Opportunities for prevention?
ESMO 2024: Best practice in HRRm testing in patients with metastatic prostate cancer
ESMO 2024: Highlights and analysis
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
CAR-T therapy and impact to cancer patient outcomes and experience of treatment
The Southeast Asian Breast Cancer Symposium; background, aims and successes
Four chemo cycles given with durvalumab and tremelimumab optimise response and tumour shrinkage in patients with mNSCLC
Neo-adjuvant therapy for different cancers in the Philippines
